Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q99684

UPID:
GFI1_HUMAN

ALTERNATIVE NAMES:
Growth factor independent protein 1; Zinc finger protein 163

ALTERNATIVE UPACC:
Q99684; Q8N564

BACKGROUND:
The Zinc finger protein Gfi-1, with alternative names Growth factor independent protein 1 and Zinc finger protein 163, is crucial for blood cell development. It functions as a transcription repressor, influencing hematopoiesis through its role in gene suppression. Gfi-1's involvement in complex formations that regulate genes essential for multilineage blood cell development, neutrophil differentiation, and granulocyte development, marks it as a key player in hematopoietic processes.

THERAPEUTIC SIGNIFICANCE:
The association of Zinc finger protein Gfi-1 with diseases such as severe congenital Neutropenia and dominant nonimmune chronic idiopathic Neutropenia of adults underscores its importance in medical research. Exploring the functions and mechanisms of Gfi-1 could lead to groundbreaking therapeutic approaches for these and potentially other hematopoietic diseases, paving the way for innovative treatments.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.